Experienced senior level executive with administrative, scientific and medical experience in managing research and development, operations, regulatory affairs, and business development. Broad range of experience includes CEO, CSO, CMO and COO positions with start-up biotechnology to Fortune 500 companies, academic institutions and venture funds. High caliber, scientific, technical and medical strategist with 25 years proven performance as a product-oriented, corporate and academic executive. Experienced in leading diagnostics, pharmaceutical and biotechnology companies in both national and international markets.
David L. Cooper, President
Ph.D. Chemistry and Molecular Biology, Florida State University
Post Doctoral Fellow, Johns Hopkins University and Fox Chase Cancer Institute
M.D. Clinical Pathology
Internship and Residency, University of Florida
Professor, University of Pittsburgh Medical Center, Division Director Molecular Diagnostics and Duke University
Chair Founding Committee Association of Molecular Pathology (AMP)
Litchfield Lecturer, John Radcliff Hospital, Oxford, England
Chief Science Officer, Quest Diagnostics
Chief Medical Officer, NimbleGen Systems, Inc.
Chief Executive Officer, NanoMedex Pharmaceuticals, Inc.
Dr. Cooper comments
Over 6,000 life science, biotechnology and medical sector companies currently are in operation in the United States (OECD 2011) and over 30,000 worldwide (USA Life Science database 2013). USPTO and international applications and allowances in these fields continue to parallel the unprecedented advance of scientific and medical knowledge. Absent the largest multi-national concerns small and mid-sized companies cannot keep pace or employ sufficient individuals conversant with the cumulative knowledge relevant to their enterprise. Even in large corporation or mature enterprise setting it is a continuing challenge for the business trained executive to first develop and then continue to increase their understanding of the underlying science upon which their company’s financial position and profitability ultimately rests. Without continued educational improvement key executive’s corporate guidance makes their company increasingly vulnerable to competition.